Taro Pharmaceutical Industries Ltd.

  • Conquer the Generic Drug Market With Taro

    By Jaiyant Cavale - July 31, 2013 | Tickers: ACT, TARO, TEVA

    Taro Pharmaceutical Industries (NYSE: TARO) hardly gets the attention it deserves. The Israel-based generic-pharmaceutical manufacturer supplies in Israel, the U.S., Canada, the U.K., Ireland and in a few other countries. The company was listed on New York Stock Exchange Euronext in March 2012 and is currently one of the best pharmaceutical companies to invest in. In this article, I shall profile this relatively unknown company and discuss why more »

  • Which Generic Drugmaker Is Your Best Buy Today?

    By Brendan O'Boyle - June 6, 2013 | Tickers: ACT, MYL, PFE, TARO

    Generic-drug makers have considerable tailwinds, making their outperformance in the past year unsurprising.  However, most companies within this sub-industry are both cheap and relatively unknown -- a combination which bodes well for investors. Here, we'll review three generic-drug makers that still trade at appealing valuations.

    How the generics game works

    Prescription drugs are split into two categories: generic and brand-name. Pharmaceutical companies develop their products through a laborious and risky more »

  • BlueMountain Capital Is Bullish On These 5 Stocks

    By Meena Krishnamsetty - May 22, 2013 | Tickers: AIG, HBI, NRG, TARO, SSP

    The New York-based hedge fund BlueMountain Capital Management has recently disclosed its first quarter equity holdings in a 13F filing with the SEC, as is consistent with the rest of its peers. Using the original 13F, seen here, let’s take a look at BlueMountain’s top five stock picks heading into the second quarter.

    A top trio

    According to the 13F, American International Group (NYSE: AIG) is the largest more »

  • Why Ackman, Icahn and Rachesky should look at TARO?

    By John A - April 28, 2013 | Tickers: TARO

    Ackman and Icahn have been fighting over Herbalife whose outcome is very hard to predict considering the complexity of determining the legality of a Multi-level marketing business as well as the international nature of Herbalife's business. Here I ask them to look at TARO which is very easy to understand and where an activist investor can easily make a difference.

    1. TARO offers compelling value link. TARO trades only more »

  • Worried About Volatility? Take A Look At These 3 Low Beta Stocks

    By Nick Chiu - April 10, 2013 | Tickers: APOL, PRA, TARO

    As market volatility picks up and “sell in May and go away” effect comes to play again, it's a good time to review stocks with low volatility, healthy balance sheets, and low valuation to better weather the fluctuating market. To find these candidates, I screened for:

    • A Beta under 0.5
    • A Debt-to-Equity ratio below 0.1
    • A P/E below 15
    • A positive EPS growth for the next more »
  • Worried about Volatility? Take a look at these 3 low beta stocks

    By Nick Chiu - April 6, 2013 | Tickers: APOL, PRA, TARO

    As the market volatility picks up and “sell in May and go away” effect comes to play again, it is a good time to review stocks with low volatility, healthy balance sheet, and low valuation to better weather through the volatile market. To find these candidates, I screened for:

    • A Beta under 0.5
    • A Debt-to-Equity ratio below 0.1
    • A P/E below 15
    • A positive EPS growth for more »
  • TARO Continues to Post Strong Results

    By John A - February 8, 2013 | Tickers: PRGO, TARO, TEVA, VRX

    Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

    Taro Pharmaceutical (NYSE: TARO) is an interesting developing story. I continue to believe that TARO's market value is significantly higher than what is reflected in today's market price. TARO's market price is effectively capped from appreciation due to a number of reasons including the pending $39.50 offer from the majority more »

  • Will This Pharma Takeover Go Through At a Higher Price?

    By Mike Thiessen - January 22, 2013 | Tickers: AZN, BMY, GSK, TARO

    Editor's Note: The previous version references Grand Slam demanding $48.50 per share. The August 2012 letter from Grand Slam Asset Management referenced $110.00 per share, not 48.50. This version has been updated.

    Taro Pharmaceutical Industries (NYSE: TARO) announced in November a further delay on a vote by minority holders of the sale of the remaining minority interest to Sun Pharmaceutical Industries (SUNP - NSE).  The minority holders more »